Unity Biotechnology Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Unity Biotechnology wird ein jährliches Gewinn- und Umsatzwachstum von 54.4% bzw. 64.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 54.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -81.5% betragen.

Wichtige Informationen

54.4%

Wachstumsrate der Gewinne

54.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	64.8%
Zukünftige Eigenkapitalrendite	-81.5%
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Jul 12

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Mar 05

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Dec 22

A Look Inside Unity Bio's Transition To An Ophthalmology Company

Nov 27

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:UBX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	26	-13	N/A	N/A	2
12/31/2025	N/A	-32	N/A	N/A	2
12/31/2024	N/A	-25	N/A	N/A	2
6/30/2024	N/A	-30	-24	-24	N/A
3/31/2024	N/A	-40	-31	-31	N/A
12/31/2023	N/A	-40	-37	-37	N/A
9/30/2023	N/A	-35	-41	-41	N/A
6/30/2023	N/A	-33	-45	-45	N/A
3/31/2023	0	-31	-49	-49	N/A
12/31/2022	0	-44	-53	-52	N/A
9/30/2022	5	-56	-46	-46	N/A
6/30/2022	5	-59	-47	-46	N/A
3/31/2022	5	-64	-45	-45	N/A
12/31/2021	5	-61	-45	-45	N/A
9/30/2021	N/A	-70	-57	-57	N/A
6/30/2021	N/A	-81	-63	-62	N/A
3/31/2021	N/A	-82	-69	-68	N/A
12/31/2020	N/A	-94	-79	-78	N/A
9/30/2020	N/A	-92	-78	-77	N/A
6/30/2020	N/A	-86	-78	-77	N/A
3/31/2020	N/A	-91	-78	-77	N/A
12/31/2019	N/A	-82	-74	-72	N/A
9/30/2019	N/A	-86	-71	-70	N/A
6/30/2019	N/A	-83	-68	-67	N/A
3/31/2019	N/A	-79	-67	-65	N/A
12/31/2018	N/A	-76	-58	-57	N/A
9/30/2018	1	-67	-57	-55	N/A
6/30/2018	1	-60	-52	-51	N/A
3/31/2018	1	-52	N/A	-42	N/A
12/31/2017	1	-45	N/A	-38	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: UBX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: UBX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: UBX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: UBX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: UBX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: UBX wird voraussichtlich in 3 Jahren unrentabel sein.

Unity Biotechnology Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 10% to US$6.00

Price target decreased by 13% to US$6.80

Price target increased by 12% to US$8.80

Price target increased by 8.8% to US$7.83

Price target decreased to US$38.00

Price target increased to US$75.17

Recent updates

UNITY Biotechnology, Inc. Announces the Appointment of Alicia Tozier as Chief Strategy Officer

Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Price target decreased by 10% to US$6.00

Insufficient new directors

Unity Biotechnology, Inc., Annual General Meeting, Jun 21, 2024

Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

Unity Biotechnology, Inc. announced delayed annual 10-K filing

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss

Insufficient new directors

Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

New major risk - Financial position

Price target decreased by 13% to US$6.80

UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

New major risk - Revenue and earnings growth

Price target increased by 12% to US$8.80

Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema (Dme)

Price target increased by 8.8% to US$7.83

Price target decreased to US$38.00

Unity Biotechnology, Inc. Announces Positive 24-Week Data from Phase 2 Behold Study of UBX1325 in Patients with Diabetic Macular Edema

Price target increased to US$75.17

Price target increased to US$90.00

UNITY Biotechnology falls 7% on reverse stock split

Price target increased to US$7.83

Unity Biotechnology, Inc. Completes Enrollment in Phase 2 Envision Study of UBX1325 in Wet Age-Related Macular Degeneration

Unity Biotechnology cuts stock sales agreement in half to $25M

Unity Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

Unity Biotechnology Announces Positive Data in Phase 2 Behold Study of Ubx1325 in Patients with Diabetic Macular Edema

Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

UNITY Biotechnology Announces Board Changes

UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

Unity Biotechnology, Inc., Annual General Meeting, Jun 24, 2022

Price target increased to US$7.50

UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degenera

Unity Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

Kristina Burow Resigns as Member of the Board and All of the Committees of the Board from Unity Biotechnology, Inc

Price target increased to US$7.50

Unity Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

Unity Biotechnology, Inc. Announces the Design for Its Phase 2 Study of Ubx1325 in Wet Age-Related Macular Degeneration and Anticipated Milestones for 2022

Chief Medical Officer notifies of intention to sell stock

A Look At Unity's UBX1325 Phase 1 Results

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell 3000E Index

Price target increased to US$6.86

UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases

Unity Biotechnology, Inc. Announces Impairment of Long Lived Assets for the Three Months Ended December 31, 2020

Price target increased to US$6.20

Unity Biotechnology, Inc. Appoints Alexander Nguyen as General Counsel

Unity Biotechnology, Inc. Announces New Preclinical Research That Reveals A Novel Mechanism for Treating Age-Related Eye Diseases

New 90-day high: US$7.51

Unity Biotechnology, Inc. Appoints Przemyslaw (Mike) Sapieha as Chief Scientific Advisor

New 90-day high: US$6.47

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Unity Biotechnology Announces Executive Changes

A Look Inside Unity Bio's Transition To An Ophthalmology Company

New 90-day high: US$4.78

Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema

New 90-day low - US$2.94

Price target lowered to US$5.67

Unity Biotechnology, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.

New 90-day high - US$9.96

Price target raised to US$23.33

Unity Biotechnology, Inc. to Report Q2, 2020 Results on Jul 31, 2020

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell Microcap Value Index

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie